Results 101 to 110 of about 24,646 (191)

Extended prophylaxis with fondaparinux versus enoxaparin against venous thromboembolism [PDF]

, 2004
Patients undergoing major orthopaedic surgery face considerable risk of venous thromboembolic complications (VTE). This paper presents cost-effectiveness analysis of extended prophylaxis with fondaparinux and enoxaparin in patients undergoing hip ...
Bjorvatn, Afsane
core  

Surveillance biologique des héparines et du fondaparinux

, 2011
Anticoagulation with unfractionated heparin, low molecular weight heparin or fondaparinux is common practice in thromboembolic disease, atrial fibrillation and mechanical heart valves.
Boehlen, Françoise, Beauverd, Yan, Louis Simonet, Martine, Fontana, Pierre   +3 more
core  

The use of fondaparinux in pregnancy [PDF]

British Journal of Haematology, 2014
Esra, Elsaigh, Jecko, Thachil, Michael J, Nash, Clare, Tower, Charles R M, Hay, Sian, Bullough, Louise, Byrd   +6 more
openaire   +2 more sources

Peak and baseline concentrations of fondaparinux during prophylactic therapy

, 2011
SummaryFondaparinux is widely approved for prophylaxis and treatment of venous thromboembolic events (VTE). However, its longer half-life time compared to heparins limits its peri-procedural use.
R. J. Ludwig, R. Kaufmann, M. Schindewolf, E. Lindhoff-Last, J. Scheuermann, Z. Wolf, W.-H. Boehncke, R. Kanagendran, H. Ackermann   +8 more
core   +1 more source

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers

, 2002
Background-The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. Current phase III trials with this synthetic selective factor Xa inhibitor focus on its use in the treatment of patients
van Aken, Benien E., Levi, Marcel, Fennema, Hein, Büller, Harry R., Bijsterveld, Nick R., Moons, Arno H., Peters, Ron J. G., Meijers, Joost C. M., Boekholdt, S. Matthijs   +8 more
core   +1 more source

Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients

, 2004
Fondaparinux efficacy for thromboprophylaxis was evaluated in predefined high-risk hip fracture patients. Patients received fondaparinux 2.5 mg for 7 days following surgery; 656 patients were randomized double blind to receive placebo or continue ...
Colwell, C. W., Jr., Eriksson, Bengt I.,, Lassen, M. R.   +2 more
core  

Fondaparinux [PDF]

, 2020
openaire   +1 more source

Fondaparinux Sodium [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist

Therapeutics and Clinical Risk Management, 2018
Kazuhiro Shimizu, Takuo Iiduka, Shuji Sato, Hajime Kiyokawa, Takahiro Nakagami, Hiroshi Mikamo, Masayo Kawazoe, Mao Takahashi, Mahito Noro Department of Internal Medicine, Toho University Sakura Medical Center, Sakura City, Chiba, Japan Background: For
Shimizu K, Iiduka T, Sato S, Kiyokawa H, Nakagami T, Mikamo H, Kawazoe M, Takahashi M, Noro M   +8 more
doaj  

Fondaparinux: A novel synthetic antithrombotic for prevention of venous thromboembolism

, 2001
Fondaparinux sodium is the first in a new class of antithrombotic medications called pentasaccharides. As a highly selective inhibitor of factor Xa, it leads to the inhibition of thrombin generation without a direct effect on thrombin itself ...
Feret, B.
core